8:00 PM Welcome and Introduction
8:05 PM Understanding the Rationale and Mechanism of Action for PARP Inhibition in MBC
8:25 PM Integrating PARP Inhibition Into Clinical Management of Patients With MBC
8:55 PM Future Directions in PARP Inhibitors in Breast Cancer: Where Do We Go From Here?
9:20 PM Final Thoughts and Audience Question and Answer Session
Date / Time
San Antonio, TX
San Antonio Marriott Rivercenter
Lee Schwartzberg, MD, FACP
West Cancer Center
Chief, Division of Hematology/Oncology
Professor of Medicine
University of Tennessee Health Science Center
Judy Garber, MD, MPH
Harvard Medical School
Director, Center for Cancer Genetics and Prevention
Dana-Farber Cancer Institute
Mark E. Robson, MD
Chief, Breast Medicine Service
Clinical Genetics and Breast Medicine Services
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with breast cancer.
This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers who care for patients with metastatic breast cancer.
- Describe the mechanism of action of the different PARP inhibitors and the rationale for PARP inhibition in treating metastatic breast cancer
- Identify patients based on molecular changes and previous therapy that are most likely to benefit from treatments with PARP inhibitors
- Integrate single-agent PARP inhibitors into the treatment of appropriately selected patients with metastatic breast cancer
- Refer eligible patients with metastatic breast cancer to clinical trials of single-agent PARP inhibitors and combinations of PARP inhibitors with other anticancer therapies
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of National Comprehensive Cancer Network and Clinical Care Options, LLC. The NCCN is accredited by the ACCME to provide continuing medical education for physicians.
The National Comprehensive Cancer Network designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 1.5 contact hours.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. NCCN designates this knowledge-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credits (Universal Activity Number: 0836-9999-18-070-L01-P).
You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit can NOT be reported. If you have not already done so, please complete your e-profile at http://www.nabp.net/ to obtain your NABP e-Profile ID.
Disclosure of Conflicts of Interest
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.